Cipla to distribute Lilly’s diabetes drugs Humalog and Trulicity in India
Cipla will expand access to Lilly’s diabetes drugs by leveraging its distribution capabilities and engaging its professionals
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Oct 21
Cipla will expand access to Lilly’s diabetes drugs by leveraging its distribution capabilities and engaging its professionals
04 Oct 21
Tecartus has received breakthrough therapy designation and a priority review from the FDA and is also being evaluated…
04 Oct 21
Merck intends to pursue the US FDA emergency use authorisation for the drug, and file regulatory applications with…
01 Oct 21
The decision was based on discouraging clinical trial data to date, including results from the recent INTR@PID study…
01 Oct 21
Cibinqo was approved in Japan based on results from four Phase 3 studies in 1,513 patients, along with…
30 Sep 21
With the transaction, the British drugmaker will obtain Caelum’s potential fibril-reactive monoclonal antibody (mAb) CAEL-101 for the treatment…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Sep 21
Merck will obtain Acceleron's medicines for rare diseases, including its pulmonary arterial hypertension (PAH) drug sotatercept
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Sep 21
The US FDA approval is based on data from a large-scale clinical programme evaluating the efficacy, safety and…
29 Sep 21
The company will focus on the development of adjuvanted recombinant vaccine candidate, in partnership with GlaxoSmithKline (GSK)
28 Sep 21
EPIC-PEP study will enrol up to 2,660 healthy participants, aged 18 years and above, who live together with…